Supprelin Implant
NDC Package 67979-002-01

11-digit billing NDC: 67979000201 · Billing unit: EA · 1 EA per package
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Supprelin (histrelin acetate) implants is sUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP).Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). This formulation utilizes a implant delivery system. Marketed by Endo Usa, Inc., this product is identified by NDC 67979-002 and is authorized under FDA application NDA022058.

Identification & Billing

NDC Package Code
67979-002-01
Package Description
1 VIAL, GLASS in 1 CARTON / 1 IMPLANT in 1 VIAL, GLASS
Product Code
67979-002
11-Digit Billing Format
67979000201
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 1294641 - Supprelin LA 50 MG (65 MCG per 24HR) Subcutaneous Drug Implant
  • RxCUI: 1294641 - histrelin acetate 0.00271 MG/HR Drug Implant [Supprelin]
  • RxCUI: 1294641 - Supprelin 50 MG (65 MCG per 24 HR) Drug Implant
  • RxCUI: 1740437 - histrelin acetate 50 MG (65 MCG per 24HR) Subcutaneous Drug Implant
  • RxCUI: 1740437 - histrelin acetate 0.00271 MG/HR Drug Implant

Clinical Specifications

Proprietary Name
Supprelin LA
Non-Proprietary Name
Histrelin Acetate
Substance Name
Histrelin Acetate
Dosage Form
Implant - A material containing drug intended to be inserted securely of deeply in a living site for growth, slow release, or formation of an organic union.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
HISTRELIN ACETATE 50 mg/1
Pharmacologic Class
Usage Information
SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP).Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment.Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia.

Regulatory & Marketing

Labeler Name
Endo Usa, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA022058
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-31-2007
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J9226
Source: ASP
Supprelin la implant
HCPCS Dosage 50 MG
Units / Pkg 1

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67979-002-01 identifies a specific commercial package of 1 vial, glass in 1 carton / 1 implant in 1 vial, glass of Supprelin LA, a human prescription drug labeled by Endo Usa, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This implant is formulated for subcutaneous use and contains histrelin acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Endo Usa, Inc. on May 31, 2007. The current certification is valid through December 31, 2026.

How is this Endo Usa, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67979000201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
67979-002-01
11-Digit CMS (5-4-2)
67979-0002-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.